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Growth factor receptor-Src-mediated suppression
of GRK6 dysregulates CXCR4 signaling and
promotes medulloblastoma migration
Liangping Yuan1, Hongying Zhang1, Jingbo Liu1, Joshua B Rubin2, Yoon-Jae Cho3, Hui Kuo Shu4,
Matthew Schniederjan5 and Tobey J MacDonald1*

Abstract
Background: Metastasis in medulloblastoma (MB) is associated with poor survival. Recent genetic studies revealed
MB to comprise distinct molecular subgroups, including the sonic hedgehog (SHH) subgroup that exhibits a
relatively high rate of progression. To identify targeted therapeutics against metastasis, a better understanding of
the regulation of MB cell migration is needed. G protein-coupled receptor kinases (GRKs) have been implicated in
cancer metastasis through their regulation of G-protein coupled receptors (GPCRs) involved in growth factor
(GF)-mediated cell migration. However, the specific roles and regulation of GRKs in MB have not been investigated.
Methods: Microarray mRNA analysis was performed for GRKs, GPCRs, and GFs in 29 human MB, and real time
RT-PCR was used to detect GRK6 expression in MB cells. Lenti- or retro-virus infection, and siRNA or shRNA
transfection, of MB cells was used to overexpress and knockdown target genes, respectively. Western blot was used
to confirm altered expression of proteins. The effect of altered target protein on cell migration was determined by
Boyden chamber assay and xCELLigence migration assays.
Results: We observed co-overexpression of PDGFRA, CXCR4, and CXCL12 in the SHH MB subtype compared to nonSHH MB (5, 7, and 5-fold higher, respectively). GRK6, which typically acts as a negative regulator of CXCR4 signaling,
is downregulated in MB, relative to other GRKs, while the percentage of GRK6 expression is lower in MB tumors
with metastasis (22%), compared to those without metastasis (43%). In SHH-responsive MB cells, functional blockade
of PDGFR abolished CXCR4-mediated signaling. shPDGFR transfected MB cells demonstrated increased GRK6
expression, while PDGF or 10% FBS treatment of native MB cells reduced the stability of GRK6 by inducing its
proteosomal degradation. Overexpression or downregulation of Src, a key mediator of GF receptor/PDGFR
signaling, similarly inhibited or induced GRK6 expression, respectively. siRNA downregulation of GRK6 enhanced
CXCR4 signaling and promoted MB migration, while lentiviral-GRK6 overexpression suppressed CXCR4 signaling,
potentiated the effect of AMD3100, a CXCR4 antagonist, and impaired migration.
Conclusions: Our findings demonstrate a novel mechanism of GF receptor/PDGFR-Src-mediated dysregulation of
CXCR4 signaling that promotes MB cell migration, which could potentially be exploited for therapeutic targeting in
SHH MB.
Keywords: GRK6, CXCR4, Growth factor receptor, PDGFR, Src, Medullobastoma

* Correspondence: tobey.macdonald@emory.edu
1
Department of Pediatrics, Aflac Cancer and Blood Disorders Center, Emory
University School of Medicine, 2015 Uppergate Drive NE, Atlanta, GA 30322,
USA
Full list of author information is available at the end of the article
© 2013 Yuan et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.

Yuan et al. Molecular Cancer 2013, 12:18
http://www.molecular-cancer.com/content/12/1/18

Background
Medulloblastoma (MB) is the most common malignant
brain tumor of childhood, and for those with metastasis the prognosis is typically poor [1]. The molecular
sub-types of MB have different rates of metastasis, but
to date, no clearly defined genetic alteration has been
linked to the initiation of metastasis [2-4]. As such, all
children with MB receive craniospinal irradiation to
treat or protect against the development of metastasis.
This treatment is suboptimal and results in excessive
neurocognitive morbidity [1]. Thus, identifying the
mechanisms of MB migration will provide invaluable
insight into MB progression, which ultimately should
lead to more effective and less toxic therapeutics for its
prevention.
Activation of growth factor (GF) receptor signaling
has been implicated in promoting cancer metastasis.
Our previous studies described overexpression of the
platelet-derived growth factor receptor (PDGFR) in
association with metastatic MB, and demonstrated that
PDGFR promotes migration through ERK-dependent activation of p21 protein (Cdc42/Rac)-activated kinase 1 (Pak1)
signaling [5,6]. More recently, PDGFR overexpression
was detected in both the primary and matched metastatic tumors derived from mouse models of MB [7].
Given the prominent association of PDGFR with MB
metastasis, we hypothesized that GF receptor signaling,
such as that by PDGFR, may also dysregulate other
GF-mediated pathways as a mechanism to potentiate
cell migration. One such candidate is the chemokine
receptor CXCR4, a member of the G protein-coupled
receptor (GPCR) family that is closely associated with
PDGFR-expressing progenitor cells [8-11]. CXCR4 plays
critical roles in the proliferation and migration of granule
cell neuron precursors during development, and is
involved in cancer metastasis [12-14]. Human stromal
cell-derived factor-1α (SDF-1α, also known as CXCL12),
binds CXCR4 and activates Gαi-mediated signaling [15].
Upon CXCL12 binding, CXCR4 dimerizes, and is in
turn phosphorylated, which induces its internalization
and lysosomal degradation resulting in signal termination [15]. Increased CXCR4 expression is associated
with aggressive cancer behavior [16]. Cho et al. reported
that the MB subgroups molecularly defined as c1 and
c3/sonic hedgehog (SHH) are responsible for the majority of relapses and death due to MB progression and
that CXCR4 is a marker for the c3/SHH subgroup [17].
A recent study confirmed that SHH signaling is
required for CXCR4 activation [18]. The desmoplastic
variant of medulloblastoma, characterized by the presence of abundant connective tissue, belongs almost
exclusively to the SHH subgroup and makes up about
50% of SHH MB, but predominantly occurs in children
less than 3 years of age. Interestingly, SHH MB with
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desmoplastic histology has a favorable prognosis,
whereas non-desmoplastic SHH MB has higher rates of
metastasis and an intermediate prognosis [4]. This
dichotomy suggests that additional modulators of SHHCXCR4 activity may determine MB clinical behavior.
G protein-coupled receptor kinases (GRKs) mediate
phosphorylation-dependent GPCR internalization and
desensitization controlling GPCR activity [19,20]. GRKs
selectively phosphorylate activated receptors, promoting
high affinity binding of arrestins, which precludes G
protein coupling [21,22]. GRKs are divided into three
subfamilies: GRK1 (GRK 1 and 7), GRK2 (GRK 2 and 3),
and GRK4 (GRK 4, 5 and 6) [23]. Regulation of GPCRs
is cell-and GRK-specific. For example, in HEK293 cells,
GRK3 and GRK6 promote CXCR4-mediated ERK1/2
activation [15]. However, in HeLa cells, GRK6 induces
CXCR4 internalization and inhibits ERK1/2 activation
[24]. Similarly, T cells from GRK6-deficient animals are
unable to migrate in response to CXCL12 [25], while
GRK6 loss in neutrophils enhances CXCL12-induced
migration [26]. Evidence indicates that GRK activity is
tightly regulated through protein interactions (e.g. Akt
or MAPK) that modulate GRK stability [27]. We thus
hypothesized that similar mechanisms exist in MB, and
report here that GRK-dependent CXCR4 activity is
dysregulated by GF receptor/PDGFR-Src signaling
resulting in the promotion of MB cell migration.

Results
Overexpression of CXCL12 and CXCR4 correlates with
SHH MB and PDGFR activity is required for optimal
CXCR4 signaling in SHH MB cells

Because of the dichotomy of clinical outcomes observed
for SHH MB, we first investigated whether the expression
profiles of CXCL12 and CXCR4 in SHH and non-SHH
MB is associated with tumor histology (desmoplastic vs.
non-desmoplastic) and clinical outcome. We performed
microarray RNA analysis on 29 primary human MB
specimens and analyzed the gene expression of members of the SHH pathway (to determine SHH from nonSHH MB), CXCL12 and CXCR4. In our cohort, 11/29
(38%) MB analyzed are SHH-active, and the mean age
in SHH and non-SHH tumors is 3.7 and 6.4 years,
respectively, which are consistent with the frequency
and age distributions observed in historical MB populations [1-4]. The percentage of desmoplastic tumors in
our cohort (10%) is also consistent with the distribution
observed in childhood MB. Consistent with reports by
others [2], all of the desmoplastic tumors in our cohort
are SHH MB, with desmoplastic tumors representing
27% of the SHH MB (Table 1). All SHH tumors demonstrate co-overexpression of CXCL12 and CXCR4, with
the exception of one tumor that was obtained after
treatment with high-dose chemotherapy. None of the
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Table 1 mRNA Expression Profile of CXCR4 and CXCL12 in SHH vs. non-SHH MB
CXCR4 relative
mRNA level

CXCL12 relative
mRNA level

DECEASED SHH

5422

1631

2 years

ALIVE

SHH

1745

217

5 years

ALIVE

SHH

6036

1707

Post-Rx

3 years

DECEASED SHH

1216

10

Diagnostic

9 months

ALIVE

SHH

6225

356

Clssic

Diagnostic

1 year

DECEASED SHH

2050

567

Classic,

Diagnostic

2 years

DECEASED SHH

3175

909

Classic

Post-Rx

2 years

DECEASED SHH

4529

623

Classic

Diagnostic

4 years

ALIVE

SHH

3864

463

SHH

Tumor
histology

Collection of
specimen

Patient age at time of
specimen collection

Patient
status

Desmoplastic Diagnostic

1 year

Desmoplastic Diagnostic
Desmoplastic Diagnostic
Anaplastic
Classic

SHH or Non-SHH

Classic

Diagnostic

5 years

ALIVE

Classic, M+

Post-Rx

7 years

DECEASED SHH

4408

149

911

2222

MBEN

Diagnostic

3 years

ALIVE

Mean ± SD

3598 ± 1915

805 ± 730

Non-SHH

138

291

Anaplastic

Diagnostic

2 years

Anaplastic

Diagnostic

6 years

ALIVE

Non-SHH

43

48

ALIVE

Non-SHH

1717

76

Classic

Diagnostic

Classic

Diagnostic

6 months

ALIVE

Non-SHH

4367

20

1 year

ALIVE

Non-SHH

339

200

Classic
Classic

Diagnostic

2 years

ALIVE

Non-SHH

107

1144

Diagnostic

2 years

ALIVE

Non-SHH

240

615

Classic

Diagnostic

2 years

ALIVE

Non-SHH

582

13

Classic

Diagnostic

3 years

ALIVE

Non-SHH

193

92

Classic

Diagnostic

5 years

DECEASED Non-SHH

185

75

Classic

Diagnostic

6 years

DECEASED Non-SHH

125

62

Classic

Diagnostic

6 years

ALIVE

28

43

Classic, M+

Diagnostic

8 years

DECEASED Non-SHH

Non-SHH

198

116

Classic

Diagnostic

11 years

ALIVE

Non-SHH

73

47

Classic

Diagnostic

11 years

ALIVE

Non-SHH

51

59

Classic

Diagnostic

11 years

ALIVE

Non-SHH

374

55

Classic

Diagnostic

12 years

ALIVE

Non-SHH

69

149

Classic

Diagnostic

16 years

ALIVE

Non-SHH

80

73

Mean ± SD

495 ± 1041

177 ± 280

Fold change SHH/
Non-SHH

+ 7X

+ 5X

SHH MB desmoplastic vs. Non-desmpplastic
Desmoplastic Diagnostic

1 year

DECEASED SHH

5422

1631

Desmoplastic Diagnostic

2 years

ALIVE

SHH

1745

217

Desmoplastic Diagnostic

5 years

ALIVE

SHH

6036

1707

Mean ± SD

4401 ± 2321

1185 ± 839

Anaplastic

Post-Rx

3 years

DECEASED SHH

1216

10

Classic

Diagnostic

9 months

ALIVE

SHH

6225

356

Classic

Diagnostic

1 year

DECEASED SHH

2050

567

Classic

Diagnostic

2 years

DECEASED SHH

3175

909

Classic

Diagnostic

2 years

DECEASED SHH

4529

623

Classic

Diagnostic

4 years

ALIVE

3864

463

SHH
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Table 1 mRNA Expression Profile of CXCR4 and CXCL12 in SHH vs. non-SHH MB (Continued)
Classic

Diagnostic

5 years

ALIVE

Classic, M+

Post-Rx

7 years

DECEASED SHH

SHH

Mean ± SD

4408

149

911

2222

3297 ± 1822

662 ± 689

SHH MB, sonic-hedgehog medulloblastoma; MBEN, medulloblastoma with extensive nodularity; M+, metastatic; Post-Rx, post-treatment.

non-SHH MB display co-overexpression, and only two
non-SHH MB demonstrate relative overexpression of
CXCR4 (Table 1). Compared to non-SHH MB, the relative mean expression of CXCR4 and CXL12 in SHH MB
is 7- and 5-fold higher, respectively (Table 1) (P < 0.01
and P < 0.05), respectively). We also examined the
expression of PDGFR pathway members for correlations
with SHH MB and found that although PDGFRA
overexpression is observed in ~50% of the non-SHH
MB, the relative mean expression level for PDGFRA is
5-fold higher in SHH MB (P < 0.01), and PDGF-A, which
only binds to PDGFRA, is 4-fold higher (P < 0.01), while
that of PDGF-D, which only binds PDGFRB, is 3-fold
higher (P < 0.01) (Table 2), suggesting that both
PDGFRA and PDGFRB are preferentially activated in
SHH MB.
Consistent with the report by Cho et al. [17], we observed that a disproportionate number of patients with
SHH tumors died of disease. Only 5/11 (45%) patients
with SHH MB are survivors beyond 5 years from diagnosis compared to 15/18 (83%) long-term survivors in the
non-SHH group (P < 0.05, two-tailed Fisher’s exact test),
(Table 1). In our cohort, there is no significant difference
in MYC expression between the SHH and non-SHH MB
(SHH MB, 645 ± 1678 vs. non-SHH MB, 1032 ± 1756,
P > 0.05). With the exception of one case, all the deaths
in the SHH MB group were of patients with tumors
having non-desmoplastic histology. In the SHH MB,
there are no obvious differences in the expression levels
of CXCR4 or CXCL12 between desmoplastic and nondesmoplastic histology, or between those alive and
deceased, although the number of desmoplastic tumors
is too small to determine statistical significance. This
suggests that if CXCR4 signaling does promote aggressive
MB behavior, then post-transcriptional factors regulating
CXCR4 activity, rather than CXCR4 or CXCL12 expression alone, must dictate this clinical phenotype.
Since we found both PDGFR and CXCR4 overexpression
in association with SHH MB, and it has been shown that
PDGF-D overexpression induces CXCR4 and promotes
metastasis in breast cancer cells [14], we postulated that
there may be a functional relationship between PDGFR
and CXCR4. To test this hypothesis, we used specific antiPDGFR function blocking antibody to treat Daoy SHH
MB cells for 24 h, then stimulated cells with PDGF and
CXCL12. Upon CXCL12 ligand binding, CXCR4 activates
ERK1/2, thus, CXCL12-induced phosphorylation of ERK

(P-ERK) is employed as a downstream marker of CXCR4
activation [24]. Our results show that PDGFR blocking
antibody abolished not only PDGF-induced P-ERK, as
expected, but also CXCL12-induced P-ERK (Figure 1A)
[P < 0.05, lane 3, 1.53 ± 0.12 vs. lane 6, 1.09 ± 0.15 by comparing the densitometry of CXCL12-induced P-ERK/ERK
between Daoy cells with or without PDGFR blocking antibody treatment, the ratio of P-ERK/ERK in lane 1 is equal
to 1.00 (100%), and the relative changes of ratio of P-ERK/
ERK in other lanes were calculated by dividing by the
ratio in lane1], indicating that PDGFR activity is required
for activation of CXCL12-CXCR4 signaling in SHHresponsive MB cells.
GRK6 is downregulated and differentially expressed in MB

G protein-coupled receptor kinases (GRKs) initiate
GPCR (CXCR4) desensitization by recruiting the binding of β-arrestins to the complex and regulate CXCR4
signaling by mediating the phosphorylation and subsequent internalization of the agonist-occupied receptor
[8]. Since we demonstrated that PDGFR activation is
required for CXCL12-mediated CXCR4 signaling, we
questioned whether PDGFR signaling functions to
suppress specific GRK expression and/or activity that
would normally act to inhibit CXCR4. To identify the
best candidate GRK to test, we first interrogated our
microarray dataset of 29 MB and found that GRK1 and 7
are not expressed by MB; however, among the structurally
related GRK4 group consisting of GRK4, 5 and 6,
GRK6 was observed to have the lowest relative expression
(P < 0.01, Figure 1B and Table 2). Since our current MB
database has too few metastatic MB to make correlations
with progression, we re-investigated our previously published MB microarray database of 9 metastatic and 14
non-metastatic MB [5] and found that the percentage of
tumors with detectable GRK6 expression is distinctly
lower in those patients with metastatic MB (22%), compared to those with non-metastatic MB (43%), while by
comparison, the percentage of tumors with detectable
GRK5 mRNA does not appear different between these
groups, suggesting that GRK6 may be differentially regulated in metastatic MB (Figure 1C). However, because of
the small sample size only a trend rather than statistical
significance could be observed. GRK4 was not analyzed in
our previous data set. GRK6 expression is not significantly
different between SHH and non-SHH MB, or between
histology type, or those alive or deceased in the SHH
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Table 2 mRNA profiles of GRKs and PDGFR/PDGF in SHH vs. Non-SHH MB
SHH MB
Pathological diagnosis

Patient status

GRK4

GRK5

GRK6

PDGFRA

PDGFD

PDGFA

Desmoplastic

DECEASED

122

215

65

941

300

666

Desmoplastic

ALIVE

140

154

56

1071

392

236

Desmoplastic

ALIVE

80

77

60

911

417

192

Anaplastic

DECEASED

49

355

117

48

454

226

Classic

ALIVE

108

78

82

723

65

237

Classic

DECEASED

118

184

86

469

139

391

Classic

DECEASED

134

235

59

2166

231

114

Classic

DECEASED

162

1253

75

926

98

471

Classic

ALIVE

60

265

84

405

80

87

Classic

ALIVE

72

148

93

773

310

91

Classic, M+

DECEASED

101

343

71

767

122

182

Mean ± SD

104 ± 36

301 ± 329

77 ± 18

836 ± 530

237 ± 145

263 ± 179

MBEN

ALIVE

171

245

72

73

155

67

Anaplastic

ALIVE

251

344

69

58

116

102

Non-SHH MB

Anaplastic

ALIVE

272

186

110

21

63

84

Classic

ALIVE

142

624

74

190

10

32

Classic

ALIVE

186

253

76

322

63

111

Classic

ALIVE

192

235

64

406

49

36

Classic

ALIVE

144

666

58

187

52

41

Classic

ALIVE

139

217

71

25

67

125

Classic

ALIVE

143

217

58

43

78

40

Classic

DECEASED

141

293

29

388

100

64

Classic

DECEASED

150

278

51

102

29

16

Classic

ALIVE

252

370

120

145

23

31

Classic, M+

DECEASED

142

454

69

727

79

172

Classic

ALIVE

242

173

70

57

245

35

Classic

ALIVE

207

435

70

49

54

44

Classic

ALIVE

220

731

81

191

58

41

Classic

ALIVE

239

142

42

61

92

84

Classic

ALIVE

285

615

88

7

68

69

Mean ± SD

195 ± 51

360 ± 186

71 ± 21

170 ± 186

78 ± 54

66 ± 40

+5X

+3X

+4X

SHH:non-SHH MB
SHH desmoplastic vs. desmoplastic MB
Desmoplastic

DECEASED

122

215

65

941

300

666

Desmoplastic

ALIVE

140

154

56

1071

65

237

Desmoplastic

ALIVE

80

77

60

911

122

182

Mean ± SD

114 ± 31

149 ± 69

60 ± 5

974 ± 85

162 ± 123

362 ± 265

Anaplastic

DECEASED

49

355

117

48

392

236

Classic

ALIVE

108

78

82

723

417

192

Classic

DECEASED

118

184

86

469

454

226

Classic

DECEASED

134

235

59

2166

139

391

Classic

DECEASED

162

1253

75

926

231

114
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Table 2 mRNA profiles of GRKs and PDGFR/PDGF in SHH vs. Non-SHH MB (Continued)
Classic

ALIVE

60

265

84

405

98

471

Classic

ALIVE

72

148

93

773

80

87

Classic, M+

DECEASED

101

343

71

767

310

91

Mean ± SD

101 ± 38

358 ± 374

83 ± 17

785 ± 623

265 ± 149

226 ± 141

SHH MB, sonic-hedgehog medulloblastoma; MBEN, medulloblastoma with extensive nodularity; M+, metastatic.

tumor group. We thus focused on GRK6 in subsequent
studies as a candidate GRK that could be involved in GF/
PDGFR-mediated regulation of CXCR4 signaling.
GRK6 expression is negatively regulated by GF receptor/
PDGFR at the transcriptional and post-translational level

Since we were unable to detect GRK6 protein by IHC in
MB (negative staining, compared to positive control in
other tissues, data not shown), we investigated MB cells
to determine whether GRK6 expression can be induced,
and if so, whether expression is dependent on GF receptor/PDGFR. To address this question, we utilized previously generated MB cells with stable knock-down of
PDGFR [6], and then investigated the level of GRK6
mRNA expression by quantitative real-time RT-PCR.
As shown in Figure 2A, GRK6 mRNA level was significantly higher in the cells with down-regulation of
PDGFR (1.5-fold increase in D556 B9 and Daoy A4

PDGFR knock-down cells, compared to the control cells
NC1; P < 0.05), indicating that GRK6 mRNA expression
is normally suppressed by PDGFR. To confirm that
PDGFR signaling regulates GRK6 protein expression,
we used Western blot to evaluate the level of GRK6 in
the PDGFR knock-down cells. As shown in Figure 2B,
the GRK6 protein level was markedly increased with or
without CXCL12 treatment (15 min) in the PDGFR
knock-down cells. Although PDGFR is reported to play
a role in medulloblastoma, other GF receptors are
involved in MB progression. We thus examined whether
generalized GF signaling is involved in the regulation of
GRK6 expression. Consistently, inhibition of GF receptor activation by GF withdrawal (starvation) similarly
increased GRK6 protein levels in MB cells, which could
be reversed back to undetectable levels by GF add-back
over 48-72 h (Figure 2C, left and middle panels). This
indicates that under normal growth conditions, MB

Figure 1 PDGFR activity is required for optimal CXCR4 signaling in SHH MB cells and GRK6 is downregulated and differentially
expressed in MB. (A) Left panel: Daoy cells were starved and treated with or without 1 μg/ml anti-PDGFRβ blocking antibody for 24 h, then
stimulated by 10 ng/ml PDGF-BB or 100 ng/ml CXCL12 (SDF-1α) for 15 min. Western blot of P-ERK shows PDGFR function is required for optimal
CXCR4 signaling; Right panel: Quantitative analysis of Western blot shows CXCL12-induced P-ERK is significantly decreased by PDGFRβ blocking
antibody (P < 0.05, lane 3, 1.53 ± 0.12 vs. lane 6, 1.09 ± 0.15, three independent experiments). (B) 29 human MB specimens were collected and
used for microarray analysis. Average expression level of GRK6 mRNA is lowest among the detectable GRKs, (P < 0.01). (C) Microarray database of 9
human metastatic and 14 non-metastatic MB showed that the percentage of tumors with detectable GRK6 mRNA was notably decreased in
metastatic MB (M+, 22%), compared to non-metastatic MB (M0, 43%). However, the percentage of tumors with detectable GRK5 mRNA was not
appreciably different in M + (22%), vs. M0 (29%).
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Figure 2 GRK6 expression is negatively regulated by GF/PDGFR. (A) Quantitative real time RT-PCR was performed to determine the
expression of GRK6 mRNA in medulloblastoma cells with normal vs. downregulated PDGFR expression. (A) GRK6 mRNA is increased 1.5 folds in B9
(PDGFRβ down-regulated by shRNA in D556, shown below left panel) and 1.5 folds in A4 (PDGFRβ down-regulated by shRNA in Daoy, shown
below right panel) respectively, compared to the parental cells (D556 NC1 or Daoy NC1), P < 0.05 (N = 3). (B) Protein level of GRK6 is increased in
D556 (B9) and Daoy (A4) with or without CXCL12 treatment. (C) D556 or Daoy was cultured in EMEM medium containing 10% serum (GF+) or
serum-free EMEM (GF-) for 24 h, then added 10% serum to the cells cultured in serum-free medium (GF add-back) and cells grown for 24-72 h.
Cell lysates were harvested for Western Blot. GF withdrawal results in robust increase of GRK6 in D556 and Daoy (left and middle panels). In right
panel, Daoy cells were starved for 24 h and then treated with 10 ng/ml PDGF-BB for 24 h. GRK6 level determined by Western blot shows marked
decrease with PDGF treatment.

Figure 3 Growth factor treatment of medulloblastoma cells induces degradation of GRK6 via the proteasomal pathway. (A) D556 or
(B) Daoy was cultured in EMEM medium with GF + or serum-free EMEM (GF-), treated with100μg/ml CHX or without CHX at indicated time
points. GRK6 level was determined by Western blot. Growth factor withdrawal increases stability of GRK6 (C) Daoy or D556 was treated with CHX
alone or CHX plus 10 μM MG132 for 8 h, then GRK6 protein level was examined by Western blot. GRK6 stability is maintained in the presence of
proteasomal inhibitor MG132.
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GRK6 is suppressed to near undetectable levels. Furthermore, treatment of Daoy cells with PDGF alone for
24 h was sufficient to induce near ablation of GRK6
(Figure 2C, right panel). These data indicate that GRK6
expression is negatively regulated by GF receptor/
PDGFR.
Although PDGFR suppresses GRK6 mRNA expression,
the marked changes in protein expression seemed to indicate that PDGFR induces additional post-translational
regulation of GRK6. To examine whether GF activation
altered the protein stability of GRK6, we treated MB cells
with 100 μg/ml cycloheximide (CHX) at the indicated
time points under normal growth conditions or without
GF (starved for 24 h prior to CHX treatment). Robust
degradation of GRK6 to a near undetectable level was
observed in cells growing in normal growth medium at
6 h after CHX treatment; however, GRK6 protein
appeared to be relatively stable in the cells grown in the
absence of GF at 6-8 h after CHX treatment (Figure 3A,
left panel and 3B). No significant difference of GRK6
protein expression was observed between cells growing in
normal growth medium and cells in medium without GF
at the indicated time points when cells were not treated
with CHX to inhibit protein synthesis (Figure 3A, right
panel). Similarly, increased GRK6 stability was observed
following CHX treatment in the PDGFR knock-down MB
cells (not shown). To test whether GRK6 undergoes
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proteasomal pathway degradation, we treated the cells
with and without the proteasome inhibitor, MG132, prior
to CHX treatment. As shown in Figure 3C, proteasomal
inhibition prevented GRK6 degradation. These data indicate that GRK6 protein stability is negatively regulated
under normal growth conditions by GFs, including PDGFR,
at the post-translational level through proteasomal
degradation.
GRK6 expression is negatively regulated in a Src-dependent
manner

Src is an important downstream effector of GF receptor/PDGFR signaling and plays a critical role in tumorigenesis [28]. To determine whether Src is involved in
the regulation of GRK6 expression at the transcriptional
level, we performed real-time RT-PCR of GRK6 mRNA
in MB cells transfected with control or Src siRNA. As
shown in Figure 4A, down-regulation of Src results in a
significant increase of GRK6 mRNA (1.5-fold increase
in D556 48 h after transfection, 3-fold increase in Daoy
96 h after transfection). At the protein level by Western
blot (Figure 4B), Src downregulation resulted in increased GRK6 levels (48 h in D556 or 96 h in Daoy after
transfection). To confirm Src’s role in regulating GRK6
expression, we generated stable MB cells for Doxycycline (Dox)-inducible overexpression of Src. Treatment
of stable MB cells with 500 ng/ml Dox for 48 h showed

Figure 4 GRK6 expression is negatively regulated in a Src-dependent manner. MB cells were transfected with control siRNA or Src siRNA,
and then the cells were harvested at 48 h (D556) or 96 h (Daoy) after transfection and examined by real time RT-PCR or Western Blot. (A) Real
time RT-PCR shows expression of GRK6 mRNA is significantly increased 1.5 folds in D556 and 3 folds in Daoy by Src siRNA transfection, P < 0.05,
respectively. Shown is the representative of three experiments. (B) Western blot shows that the protein level of GRK6 is increased by Src siRNA.
(C) Retro-X Tet on Src-inducible stable cell line was treated by 500 ng/ml Dox for 48 h, and then, Src and GRK6 expression were examined by
Western blot. Src- induced expression results in decreased GRK6 protein level.
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that Src overexpression resulted in decreased GRK6,
compared to the same cells without Dox treatment
(Figure 4C). Dox treatment had no effect on Src or
GRK6 expression in non-transfected parental cells (not
shown). Using the Src inhibitor, dasatinib, our data indicate that pharmacologic Src blockade can also induce
GRK6 expression (not shown). These data demonstrate
that Src, a major downsteam effector of PDGFR and
other GF-activated pathways, is sufficient to mediate
negative regulation of GRK6 expression.
CXCR4 signaling and MB cell migration is inhibited by
GRK6

To test the function of GRK6 in MB cells, we first used
specific GRK6 siRNA to down-regulate GRK6 expression
in MB cells and examined the impact of altered GRK6 expression on CXCL12/CXCR4 signaling and cell migration.
As shown in Figure 5A, GRK6 down-regulation enhanced
CXCL12-mediated phosphorylation of ERK (P-ERK)
compared to cells transfected with control siRNA, indicating that GRK6 normally acts to suppress CXCR4
signaling in MB cells. Expression of GRK5, which shares
a sequence similar to GRK6, was not affected by GRK6
siRNA transfection. We subsequently demonstrated
using Boyden chamber migration assays that serummediated cell migration was significantly enhanced in the
GRK6 down-regulated MB cells (Figure 5B). Consistent
with these results, we found that Src overexpression,
which we showed reduces GRK6 expression, similarly promotes cell migration in a scratch assay (data not shown).
To confirm the role of GRK6 in MB cells, we used
lentiviral FUW-mCherry (control) and FUW-C-GRK6
to generate stable MB cells overexpressing GRK6. As
shown in Figure 6A, CXCL12-mediated P-ERK was decreased in cells with GRK6 overexpression, compared to
control cells. Furthermore, treatment of cells with
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AMD3100, an antagonist of CXCR4, at 2.5 μg/ml
completely abolished CXCL12-induced P-ERK in FUWGRK6, but not in FUW-Cherry cells (Figure 6A, right
panel) [P < 0.05, lane 3, 0.59 ± 0.1 vs. lane 6, 0.31 ± 0.03
by comparing the densitometry of CXCL12-induced PERK/ERK in Daoy cells with or without overexpression
of GRK6. The ratio of P-ERK/ERK in lane 1 is equal to
1.00 (100%)], indicating that GRK6 overexpression
potentiates the effect of AMD3100. In Boyden chamber
migration assays, we found that MB cell migration was
significantly inhibited by overexpression of GRK6
(Figure 6B). Similar results were observed in scratch
assays (data not shown). To further validate the role of
GRK6 in MB cells, we conducted cell migration and
proliferation assays using xCELLigence [29], which allows for monitoring cell activity in real-time. As shown
in Figure 6C (left panel), migration in serum-free conditions is similar between FUW-Cherry and FUW-GRK6
cells; however, in the presence of serum, migration is
significantly decreased in FUW-GRK6 cells compared
to control FUW-Cherry cells. At approximately 16.5 h,
the average cell index (number of migratory cells) in
FUW-Cherry is 1.7-fold higher than in FUW-GRK6
cells (P < 0.01). To assess whether the difference in migration was the result of differences in cell viability and
proliferation, we simultaneously performed a proliferation assay at the beginning of the migration assay. The
results showed no significant difference in the proliferative capacity of the control and GRK6 overexpressing
cells at either high (2 × 104/well) or low (5 × 103/well)
cell density (Figure 6C, right panel). Together, these
data indicate that in these MB cells GRK6 functions to
suppress CXCR4 signaling and inhibit cell migration,
and thus optimal signaling and migration is maintained
through ongoing suppression of GRK6 levels and
activity.

Figure 5 CXCR4 signaling and MB cell migration is inhibited by GRK6. (A) D556 or Daoy was transfected with control siRNA or GRK6 siRNA.
The cells were starved for 24 h after transfection and then stimulated by 100 ng/ml CXCL12 (SDF-1α) for 15 min. The results show that downregulation of GRK6 causes increased CXCL12-induced P-ERK in both cell lines. (B) Daoy was transfected with control siRNA or GRK6 siRNA and
then starved for 24 h prior to examination by Boyden chamber migration assay. Results show serum-mediated migration is significantly increased
in the cells transfected with GRK6 siRNA (P < 0.01).

Yuan et al. Molecular Cancer 2013, 12:18
http://www.molecular-cancer.com/content/12/1/18

Page 10 of 14

Figure 6 Overexpression of GRK6 inhibits CXCR4 signaling and cell migration. (A) Left panel: Lentiviral FUW-Cherry (control) or FUW-Cherry
-GRK6 (FUW-GRK6)- infected Daoy cells were serum-starved and treated with AMD3100, an antagonist of CXCR4, for 24 h prior to CXCL12 (SDF1α) stimulation (100 ng/ml for 15 min). The results show that overexpression of GRK6 inhibits CXCL12-induced P-ERK and CXCL12-induced P-ERK
is completely abolished by AMD3100 at 2.5 μg/ml in Daoy-FUW-GRK6 cells, not in Daoy-FUW-Cherry cells, that potentiates the CXCR4 inhibitory
effect of AMD3100. GRK5 serves as internal control (no change) to demonstrate that effects are GRK6-specific; Right panel: Quantitative analysis of
Western blot shows CXCL12-induced P-ERK is significantly inhibited by AMD3100 treatment in Daoy with overexpression of GRK6 [P < 0.05, lane 3,
0.59 ± 0.1 vs. lane 6, 0.31 ± 0.03, the ratio of P-ERK/ERK in lane 1 is equal to 1.00 (100%), three independent experiments]. (B) Boyden chamber
migration assay shows that serum-mediated migration is significantly decreased in cells with FUW-GRK6 overexpression (P < 0.01), compared to
FUW-Cherry control cells. (C) xCELLigence was used to monitor real-time cell migration and proliferation. In the left panel, the results show that
serum-mediated cell migration is significantly decreased in the cells with FUW-GRK6 overexpression (the upper two lines represent the migration
of either FUW-Cherry or FUW-GRK6 in serum-containing medium. The bottom two lines represent the migration of either FUW-Cherry or FUWGRK6 in serum-free medium). In the right panel, the results show that overexpression of GRK6 has little effect on cell proliferation either at high
cell density (2 × 104/well, 20 K) or low cell density (5 × 103/well, 5 K).

Discussion
Children diagnosed with sonic hedgehog-activated MB
(SHH MB) displaying desmoplastic histology have a
good prognosis, while those with non-desmoplastic
histology have higher rates of metastasis and an intermediate prognosis, indicating that additional factors
to SHH activation account for the clinical dichotomy
observed [2-4,17]. Recent evidence shows that CXCR4
signaling, which is critical to the proliferation and
migration of granule neuron precursors during development, is dependent on SHH for its activation in
MB [13,18,30,31]. This finding, coupled to CXCR4’s
reported role in tumor progression [14,16,32,33],
point towards dysregulated CXCR4 signaling as a

possible key determinant of SHH MB clinical behavior. We observe high co-expression levels of CXCR4
and CXCL12, as well as PDGFRA, distinctly associated
with SHH MB. Herein, we demonstrate that GF receptor/PDGFR and Src, a major GF/PDGFR downstream effector, act to suppress the expression and
stability of the G protein-coupled receptor kinase
GRK6 in MB cells, which in turn functions to maintain CXCR4 signaling and promote cell migration,
thereby identifying a new mechanism for the
dysregulation of this signaling axis in MB. This finding has important implications for our understanding
of SHH MB clinical behavior and potential translation
to therapeutic targeting.
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GPCRs are desensitized by agonist-induced GRKmediated phosphorylation, whereby the receptors are
uncoupled from heterotrimeric G-protein signaling.
Suppression of GRKs, and loss of GRK-mediated desensitization, can result in the prolonged activation of
GPCRs. The involvement of CXCR4 in cancer metastasis
appears to be due to dysregulation of the receptor leading
to enhanced CXCR4 signaling [14,24]. In breast cancer
cells, a similar functional relationship between the PDGFR
pathway and CXCR4 has been reported, whereby overexpression of PDGF-D, which specifically binds to and activates PDGFRB, was shown to induce CXCR4 expression
and promote lymph node metastasis [34]. GRKs can also
regulate EGFR and PDGFR activity, and in turn, GRKs
may be regulated at the mRNA and protein level by
altered oncogenic receptor signaling [35].
The description of GRK6 expression and its functional
role in cancer is very limited, and until now, has not
been reported in MB. In this study, we found that the
percentage of GRK6 expression is lower in MB tumors
with metastasis (22%), compared to those without metastasis (43%); however, these data revealed only a trend
in MB, with the difference not being statistically significant due to the small sample size. GRK6 typically has a
negative regulatory role in CXCR4 activation and
CXCL12-induced cell migration [24,26]. For example,
GRK6 deficiency is associated with impaired desensitization and enhanced CXCR4-mediated neutrophil migration and has been implicated in the pro-inflammatory
response seen in rheumatoid arthritis [26,36]. However, in
HeLa cells, siRNA-based functional screening identified
GRK6 as a critical positive regulator of integrin-mediated
cell adhesion and migration [37]. Similarly, GRK6 silencing in myeloma cells induced a tumor suppressor effect
by inhibiting STAT3 phosphorylation and decreasing
tumor cell survival [38].
To date, we have little knowledge regarding the regulation of GRK6. Herein, we demonstrate that GF/PDGFRSrc activation results in decreased expression of GRK6 at
the transcriptional and post-translational level to maintain
optimal CXCR4 signaling. In fact, we found that Src, a key
mediator of PDGFR signaling and other GF-induced pathways [28], can independently regulate GRK6 expression,
indicating that Src could be a critical therapeutic target in
MB, especially given its additional role as a central node
in other pro-migratory and pro-survival signals. This
therapeutic potential is further illustrated in our study,
which shows that targeting CXCR4 with the inhibitor
AMD3100, can be potentiated by the overexpression of
GRK6. Since we show that Src suppresses GRK6, Src
inhibitors could potentially be used to elevate levels of
suppressive GRK6. Given that we have previously shown
that PDGFR can regulate Rac1-Pak1 signaling important
for cytoskeletal rearrangements required for MB cell
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migration [6], it remains to be seen whether the combined
inhibition of PDGFR-Src-CXCR4 may act synergistically
to suppress SHH MB growth and progression. In our
study, the observation that specific alteration of GRK6 did
not itself impact MB cell growth indicates that GRK6 is a
critical mediator of GF receptor/PDGFR-Src oncogenic
signaling for CXCR4-mediated migration, but is not
essential for maintaining CXCR4-mediated growth. Rather, other mechanisms, and perhaps other GRKs may be
necessary to regulate growth. Although we focused on
GRK6 in this study because of its apparent dysregulated
expression in metastatic MB, it is possible that other
GRKs that we found expressed by MB (i.e. GRK4
and 5) may also play a role in MB growth and progression. For example, PDGFR/Src has been shown
to regulate GRK2 activity in other cell types and the
suppression of GRK3 appears necessary for maximal
glioblastoma cell growth [35,39]. Further studies will
be necessary to investigate the potential functional
role and regulation of GRK4 and GRK5 in MB as
well as the effect of targeting GRKs and PDGFR-Src
dysregulation of the CXCR4 signaling axis on MB
progression in vivo.

Conclusion
In summary, we found that GF receptor/PDGFR-Srcmediated suppression of GRK6 acts to promote CXCR4
signaling and cell migration irrespective of CXCL12 ligand and demonstrate a novel mechanism of GF receptor/
PDGFR-Src-mediated dysregulation of CXCR4 signaling
that promotes MB cell migration, and thus targeting this
axis in SHH MB could represent a potent new therapeutic
strategy for MB.
Methods
Cell culture and reagents

Daoy and D556 human medulloblastoma cells were
cultured in EMEM with 10% fetal bovine serum (FBS).
CXCL12 and anti-human PDGFRβ antibody (blocking
antibody, cat# AF385) were purchased from R & D
Systems (Minneapolis, MN).
Patient samples

MB frozen tumor specimens were consented for and
obtained from the Children’s Healthcare of Atlanta
(CHOA) (n = 29) tumor tissue repository. The research
protocols and amendments were approved by the institutional review boards of CHOA, Emory University, and
the CHOA tumor bank committee. All tumor specimens
were studied as deidentified tissue samples and reviewed
as part of this study by board certified neuropathologist
(MS) according to WHO criteria (2007).
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Expression profiling

RNA was extracted from 29 frozen MB tumor samples
using the Trizol reagent (Invitrogen, Carlsbad, CA) and
was profiled by AROS Biosciences on the Affymetrix human genome U133 Plus 2.0 array with the 30 IVT Express
Labeling Kit (Affymetrix, Santa Clara, CA). CEL files were
preprocessed using RMA [40] and probesets collapsed to
genes using the Genepattern software suite (http://www.
broadinstitute.org/cancer/software/genepattern/). Sample
were then assigned to a molecular subgroups as previously
described, using a classifier based on support-vector
machines [17]. In addition, the database from previously
published microarray expression profiling of medulloblastoma [5] was used to supplement mRNA profiling
data analysis of metastatic vs. non-metastatic medulloblastoma. The relative mean expression level listed for
each gene is calculated by the Affymetrix software.
Western blot

Western blot of whole cell lysates harvested in lysis buffer
(Cell Signaling Technology, Danvers, MA) was performed
with the following primary antibodies: GRK5, GRK6 and
PDGFRβ (Santa Cruz, CA); phospho-PDGFRβ (Tyr751),
phospho-ERK and ERK1/2 (Cell Signaling Technology).
Goat anti-mouse or rabbit horseradish peroxidase secondary antibodies (Santa Cruz) were used and the immunoreactive bands were detected by ECL. Densitometric
analysis of the visualized bands was used to quantitate and
compare the relative changes in levels of target proteins.
Real time RT-PCR

Total RNA was prepared from human MB cell lines
(Daoy or D556). Random-primed single-stranded cDNA
was made from total RNA by using the Superscript III
kit (Cat# 18080-051, Invitrogen, Carlsbad, CA). The
following oligonucleotides as primers were used for real
time PCR: Glyceraldehyde-3-phosphate dehydrogenase
(GAPDH), 5′- C G T G C CGCCTGGAGAAACC-3′ (forward), 5′T GGA A GAGTGGGAGTTGCTGTTG-3′ (reverse). Human GRK6 primers were purchased from
Qiagen (cat# QT00043295). GRK6 cDNA was amplified
by real-time PCR (35 cycles: 95°C for 10 min, 94°C for
1 min, 55°C for 1 min, 72°C for 1 min, extension 72°C
for 8 min) in real-time cycler from Applied Biosystems
(Foster City, CA). Each sample was set at least in triplicate for each PCR. Data analysis was performed
according to the absolute standard curve method. Data
are presented in relation to the respective housekeeping
gene and normalized the fold change of control cells to
1, then calculated the relative fold changes.
SiRNA and shRNA transfection

Human GRK6 ON-TARGETplus SMARTpool siRNA
(L-004627-00-0005), Src ON-TARGETplus SMARTpool
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siRNA (L-003175-00-0005) and negative control nontargeting siRNA (D-001810-01-05) were purchased
from Dharmacon (Chicago, IL). Each SMARTpool is a
mixture of 4 siRNA sequences with advantages in both
efficacy and specificity. For siRNA transfections, 1.5 × 105
cells were seeded in each well of a six-well plate and
grown to 50-60% confluency prior to transfection. Cells
were transfected with siRNA using Lipofectamine 2000
(Invitrogen, Carisbad, CA) for 48-96 h according to the
manufacturer’s instruction and then cells were treated
and harvested for further experiments. The stable
shPDGFR and control shRNA cells (Daoy and D556)
used in these experiments were previously generated by
us as described [6].
GRK overexpressing cells

The lentiviral FUW-mCherry and FUW-C-GRK6 were
kindly provided by Dr. Joshua Rubin (Washington
University in St Louis, MO). To make stable medulloblastoma cell lines with overexpression of GRK6, 4 × 105 cells
were seeded in 60 mm dishes before infection and then,
lentiviral FUW-mCherry and FUW-C-GRK6 were added
into each dish for 6 h. Media was changed and cells grown
for 2 or 3 days before cell-sorting per the flow cytometry
core facility protocols to separate sort-positive and sortnegative cells. Western Blots were performed at least three
times to verify the stable cells.
Src overexpressing inducible cells

The plasmid pRetro HA-Src A was kindly provided by
Dr. Hui Kuo Shu (Emory University, Atlanta, GA). Briefly,
pCSrc A HA14 plasmid was first digested with Xho1,
filled in with T4 polymerase and finally digested with
BamH1. The excised HA-Src A cDNA was inserted into
the cloning sites between BamH1 and Nru1 of pRetroXTight-Pur (Clontech, Mountain View, CA, USA). The
regulatory vector and the pRetro HA-Src A were
transfected into phoenix-ampho package cells and then
the supernatant was harvested to infect MB cell lines. The
cells were selected by G418 plus puromycin after infection. 500 ng/ml doxycycline (Dox) was added to induce
expression of Src. The overexpression of Src was identified
by Western Blot.
Boyden chamber migration assay

Fibronectin-mediated cell adhesion and migration was
assessed using the QCM-FN Quantitative Cell Migration
Assay (cat# ECM580, Millipore). Briefly, cells were cultured to 80% confluency and harvested with trypsin/
EDTA and resuspended in serum-free EMEM. 1.0 × 105
cells in 200 μL serum-free EMEM were seeded into the
pre-coated (fibronectin or BSA) upper chambers. The
lower well contained 500 μL EMEM with 10% FBS. Each
chamber was set in triplicate. The cells were incubated for
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4-5 h at 37°C, stained with cell staining solution and then
washed in distilled water. Cells were eluted with extraction
solution and 100 μL transfered to a 96-well microtiter
plate for absorbance reading (570 nm).
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xCELLigence migration and proliferation assays
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xCELLigence instrumentation and protocols for the measurement of real-time migration and proliferation were
provided by Roche Diagnostics Corporation. xCELLigence
is an electrical impedance-based system that allows for the
measurement of real-time cell migration and proliferation
[29]. We used CIM plate (Cat# 05665817001, Roche) for
migration assay and the E-plate (Cat# 05469830001,
Roche) for proliferation assay. Briefly, for migration assay,
we seeded 4 × 104 cells into each chamber and set 4 chambers for each cell type. After all chambers were set up, the
CIM plate was put into xCELLigence instrument at 37°C,
5% CO2 incubator for migration assay. Similarly, we
seeded 2 × 104 cells or 5 × 103 cells into each well and set
up 4 wells for each cell type, then ran proliferation assay
in xCELLigence instrument at 37°C, 5% CO2 incubator.
The impedance was recorded in 15 min intervals.
Statistical analysis

Group differences and p-values were calculated using
Student’s t-test. Difference of group percentage was
calculated using Fisher’s exact test. P values < 0.05 were
considered as statistically significant.
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